There is an urgent need to identify the best ways to manage breast cancer in women in the Asia–Pacific region. It is increasingly recognized that disease patterns, efficacy and toxicities of various treatment regimens, differ between Asia–Pacific women and women in the West. Despite these differences, breast cancer treatment in the Asia–Pacific region often follows evidence-based treatment guidelines based on Western clinical trials. To obtain the best possible outcomes in the Asia–Pacific region, country-specific breast cancer clinical trials and registries are crucial. Findings should be integrated into country-specific consensus treatment guidelines. These measures would facilitate the best choice of drugs, the optimal doses, and the optimal schedules for treating women with breast cancer in the Asia–Pacific region.